↑ 疾患リストへ ← 戻る

 300. IgG4関連疾患 [臨床試験数:20,薬物数:19(DrugBank:13),標的遺伝子数:8,標的パスウェイ数:72] 

Searched query = "IgG4-related disease", "Autoimmune pancreatitis", "IgG4-related sclerosing cholangitis", "IgG4-related lacrimal gland, orbital, and salivary gland lesions", "IgG4-related kidney disease"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04125511November 1, 20194 November 2019Characterizing IgG4-RD With 68Ga-FAPI PET/CTCharacterizing IgG4-related Disease With 68Ga-FAPI PET/CTIgG4-related DiseaseDrug: 68Ga-FAPIPeking Union Medical College HospitalNot recruiting18 Years90 YearsAll100Early Phase 1
2NCT04124861October 15, 201922 October 2019Withdraw Drug in Stable IgG4-Related DiseaseEvaluation and Prediction of Relapse Risk After Glucocorticoid and Immunosuppressant Withdrawal in Patients With Stable IgG4 Related Disease: An Open-labeled Multi-centric Randomized Controlled Study From ChinaAutoimmune DiseasesDrug: Drug free, IS monotherapy and GC combined with ISPeking Union Medical College HospitalChinese PLA General Hospital;Peking University People's Hospital;The People's Hospital of Hebei Province;Shengjing Hospital;Tongji HospitalNot recruiting18 Years70 YearsAll138N/A
3NCT03669861November 13, 201826 November 2018Safety and Efficacy of Abatacept in IgG4-Related DiseaseA Prospective, Open-label, Single Center Abatacept in IgG4-Related Disease 10-patient Proof-of-concept StudyIgG4-related DiseaseDrug: AbataceptMassachusetts General HospitalBristol-Myers SquibbRecruiting18 YearsN/AAll10Phase 2United States
4JPRN-UMIN0000307352018/01/1522 July 2019Diagnostic accuracy of contrast enhanced endoscopic ultrasonography in pancreatbiliary diseaseDiagnostic accuracy of contrast enhanced endoscopic ultrasonography in pancreatbiliary disease - A clinical trial of contrast enhanced endoscopic ultrasonography in the pancreatobiliary diseasePancreas tumor, Chronic pancreatitis, Autoimmune pancreatitis, Gallblader polyp, Biliary tract tumorContrast enhanced endoscopic ultrasonography using perflubutane
MRI
enhanced CT
endoscopic ultrasonography without perflubutane
Department of Endoscopy The Jikei University School of MedicineNot Recruiting20years-old100years-oldMale and Female786Not selectedJapan
5NCT03368274September 1, 201711 June 2018To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild SymptomTo Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild SymptomIgG4-related DiseaseDrug: T 614Wen ZhangRecruiting18 Years70 YearsAll30Phase 4China
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2017-002214-31-BE26 November 2018Study to Evaluate The Safety And Effectiveness of XmAb®5871 In Patients With IgG4-Related Disease (INDIGO)A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XmAb®5871 in Patients with IgG4-Related Disease (INDIGO)IgG4-Related Disease
MedDRA version: 20.0 Level: LLT Classification code 10071581 Term: IgG4 related sclerosing disease System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Code: XmAb5871
Pharmaceutical Form: Solution for injection/infusion
INN or Proposed INN: XmAb5871
Current Sponsor code: XmAb5871
Other descriptive name: XMAB5871
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 125.0-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use
Xencor, Inc.Not AvailableFemale: yes
Male: yes
240Phase 3United States;Spain;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Canada;Poland;Belgium;Germany;Netherlands;Sweden
7EUCTR2017-002214-31-NL20 August 2018Study to Evaluate The Safety And Effectiveness of XmAb®5871 In Patients With IgG4-Related Disease (INDIGO)A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XmAb®5871 in Patients with IgG4-Related Disease (INDIGO)IgG4-Related Disease
MedDRA version: 20.0 Level: LLT Classification code 10071581 Term: IgG4 related sclerosing disease System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Code: XmAb5871
Pharmaceutical Form: Solution for injection/infusion
INN or Proposed INN: XmAb5871
Current Sponsor code: XmAb5871
Other descriptive name: XMAB5871
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 125.0-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use
Xencor, Inc.Not AvailableFemale: yes
Male: yes
240Phase 3United States;Spain;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Canada;Poland;Belgium;Netherlands;Germany;Sweden
8JPRN-UMIN0000226332016/06/062 April 2019Efficacy and safety of low-dose steroid treatment in asymptomatic patients with autoimmune pancreatitis.autoimmune pancreatitisSteroid treatment (total 56 weeks)

Induction ~ 4 weeks : Prednisolone 10mg/day
4 weeks ~ 48 weeks : Prednisolone 5mg/day
48 weeks ~ 52 weeks : Prednisolone 2.5mg/day
52 weeks ~ 56 weeks : Prednisolone 1mg/day
Osaka UniversityNot Recruiting20years-oldNot applicableMale and Female20Not selectedJapan
9NCT02797665May 201620 August 2018Treatment of Obstructive Jaundice in Autoimmune Pancreatitis and/or Immunoglobulin G4-related Sclerosing Cholangitis by CorticosteroidsAutoimmune Pancreatitis;IgG4-related Sclerosing Cholangitis;Obstructive JaundiceDrug: corticosteroids;Procedure: biliary stentPeking Union Medical College HospitalNot recruiting18 YearsN/AAll30N/AChina
10NCT02705638April 201615 July 2019Treatment of IgG4-Related Disease With Revlimid and RituximabTreatment of IgG4-Related Disease With Revlimid and Rituximab: The TIGR2 TrialImmunoglobulin G Subclass 4 Related Disease;IgG4-related Disease;Autoimmune Pancreatitis;IgG4-related Sclerosing Cholangitis;Retroperitoneal FibrosisDrug: Rituximab;Drug: LenalidomideMayo ClinicCelgene CorporationNot recruiting18 YearsN/AAll6Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT02703194March 201618 March 2019Leflunomide for Maintenance of Remission in IgG4 Related DiseaseA Study of Safety and Efficacy of Leflunomide for Maintenance of Remission in IgG4 Related DiseaseImmunoglobulin G4 Related Sclerosing DiseaseDrug: Prednisone;Drug: LeflunomideChinese PLA General HospitalNot recruiting18 Years80 YearsAll68Phase 4China
12NCT02725476March 201618 December 2018Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)An Open-label, Single-arm, Pilot Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related DiseaseIgG4-RDBiological: XmAb5871Xencor, Inc.Massachusetts General HospitalNot recruiting18 Years80 YearsAll20Phase 2United States
13JPRN-UMIN0000199082016/01/012 April 2019Preliminary study of [11C]methionine PET/CT in the diagnosis of IgG4 related diseaseIgG4 related disease[11C]methionine PET/CT, [18F]FDG PET/CTSaitama Medical University International Medical CenterSaitama Medical University HospitalNot Recruiting20years-oldNot applicableMale and Female30Not selectedJapan
14NCT02458196April 201516 December 2017Study of Treatment Response on IgG4 Related Disease (IgG4RD)A Randomized Trial of Treatment in Patients With IgG4-Related DiseaseAutoimmune DiseaseDrug: Prednisone;Drug: Prednisone and Mycophenolate mofetilPeking Union Medical College HospitalRecruiting18 Years70 YearsAll60Phase 2China
15NCT01758393December 201219 February 2015Glucocorticoids in Patients With IgG4-RDA Randomized Trial of Glucocorticoids in Patients With IgG4-Related DiseaseIgG4-related DiseaseDrug: PrednisonePeking Union Medical College HospitalRecruiting18 Years70 YearsBoth40Phase 2/Phase 3China
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT01665196September 201216 December 201718F-FDG PET/CT for IgG4-Related DiseaseEvaluation of 18F-FDG PET/CT in Diagnosis and Response Assessment of Patients With IgG4-Related DiseaseAutoimmune DiseaseDrug: 18F-FDGPeking Union Medical College HospitalRecruiting18 Years75 YearsAll100Early Phase 1China
17NCT02899039July 201226 September 2016Follicular Helper T Cells: Biological Marker and Involvement in the Physiopathology of the IgG4-related DiseaseFollicular Helper T Cells: Biological Marker and Involvement in the Physiopathology of the IgG4-related DiseaseIgG4-related DiseaseBiological: extra blood draw samplesAssistance Publique Hopitaux De MarseilleNot recruiting18 YearsN/ABoth75N/AFrance
18NCT01584388April 201216 December 2017Rituximab in IgG4-RD: A Phase 1-2 TrialRituximab (RTX) for IgG4-related Disease (IgG4-RD): a Prospective,Open-label TrialRetroperitoneal Fibrosis;Autoimmune Pancreatitis;Sialadenitis;PseudotumorDrug: RituximabMassachusetts General HospitalGenentech, Inc.Not recruiting18 YearsN/AAll30Phase 1/Phase 2United States
19JPRN-UMIN0000038042010/05/012 April 2019Randomized controlled trial which examines whether resuming steroid can prevent clinical relapse in the patients with asymptomatic high levels of serum IgG after ceasing steroid therapy for autoimmune pancreatitisautoimmune pancreatitisPrednisolone at a dose of 10mg/day is started. The dose is taperd by 2.5mg every 8-10 weeks until reaching 5mg/day.
Maintenance therapy at a dose of 5 mg/day is continued.
Resuming or increasing prednisolone is not planned. Patients during the course of tapering prednisolone continue to taper the dose until its complete cessation.
Department of Gastroenterology, University of TokyoRecruiting20years-oldNot applicableMale and Female20Not applicableJapan
20NCT00588367April 200628 April 2015CT Pancreas PerfusionCT Perfusion of Pancreatic Cancer and Chronic Pancreatitis: Feasibility StudyPancreatic Ductal Adenocarcinoma;Chronic Pancreatitis;Autoimmune PancreatitisDevice: Mayo Interactive Breath Hold MonitorMayo ClinicNot recruiting18 YearsN/ABoth30N/AUnited States

先頭へ